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Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of future
cardiovascular events. Despite compelling evidence about the efficacy of secondary prevention, a substantial gap
exists between risk factor management in real life and that recommended by international guidelines. Moreover,
stroke is a leading cause of disability and morbidity which partly emerges from post-stroke complications.
Methods/design: We designed a block-randomised (2:1 ratio) open pragmatic trial [NCT02156778] with blinded
outcome assessment comparing STROKE-CARD to usual post-stroke-patient care. STROKE-CARD is a multifaceted
post-stroke disease management program with the objective of reducing recurrent cardiovascular events and improving
quality of life in ischaemic stroke and TIA-patients. It combines intensified multi-domain secondary prevention, systematic
detection and treatment of post-stroke complications, and patient self-empowerment. Enrolment of 2160 patients with
acute ischaemic stroke or TIA (ABCD2-Score≥ 3) is planned at two study centres in Austria. The co-primary efficacy
endpoints are (i) the composite of major recurrent cardiovascular events (nonfatal stroke, nonfatal myocardial infarction,
and vascular death) occurring within 12 months after the index event and (ii) one-year health-related quality-of-life
measured with the European Quality of Life-5 Dimensions (EQ-5D-3 L) questionaire. Secondary endpoints include all-
cause mortality, functional outcome, and target-level achievement in risk factor management.
Discussion: This trial will provide evidence on whether the pragmatic post-stroke intervention program STROKE-CARD
can help prevent cardiovascular events and improve quality-of-life within the setting of a high-quality acute stroke care
system. In case of success, STROKE-CARD may be implemented in daily clinical routine and serve as a model for other
disease management initiatives.
Trial registration: ClinicalTrials.gov: NCT02156778. (June 5, 2014, retrospectively registered).
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Stroke is the second leading cause of death and one of the
leading contributors to disability worldwide [1, 2]. While
the age-standardised incidence of stroke is decreasing in
high-income countries due to improved health care ser-
vices and primary prevention, the absolute number of
stroke patients is still on the rise, mainly based on con-
tinuous population aging and growth [3]. Stroke survivors
represent a population-segment particularly vulnerable to
further cerebro- and cardiovascular events. Apart from
persistent deficits, potentially avoidable medium- and
long-term post-stroke complications are significant con-
tributors to functional impairment and an appealing target
for concerted interventions.
The risk of stroke recurrence is high at up to 10% within
one year and more than 25% within 5 years [4]. Recurrent
strokes account for about one fifth of all strokes in
state-wide registries [5], have a worse clinical outcome,
have a higher fatality rate, and cause higher healthcare
costs than first-ever strokes [6].
More than 90% of the global stroke burden is attribut-
able to modifiable risk factors, including behavioural and
metabolic factors [7, 8] and most patients with acute is-
chaemic stroke have one or more un- or insufficiently
controlled risk factors - a condition recently termed “pre-
ventable stroke” [9]. Vice versa, current evidence-based
secondary prevention strategies combining behavioural
and pharmacological interventions were estimated to
reduce the risk for recurrent vascular events by more
than 80% [10]. In real life, however, prevention goals
and target levels of risk factors are rarely achieved
[11, 12]. Furthermore, discontinuation of prescribed
medications represents a major challenge in patient
management, occurring in roughly one-third of is-
chaemic stroke patients within the first year of hos-
pital discharge [13].
Multimodal and multi-disciplinary interventions within
the framework of structured disease-management pro-
grams have been shown to improve quality of care and
outcomes in patients with various chronic diseases other
than stroke [14, 15]. Also, digital health care interventions
are a promising novel tool to improve individualised risk
factor management [16].
To address the substantial gap between risk factor man-
agement in real life and that recommended by international
guidelines, we designed the STROKE-CARD program,
which is a multifaceted pragmatic post-stroke disease man-
agement program combining intensified multi-domain sec-
ondary prevention, detection and treatment of post-stroke
complications, and patient self-empowerment. In a prag-
matic trial, we compare STROKE-CARD to usual care in
its ability to reduce rates of recurrent cardiovascular events
and improve quality-of-life in ischaemic stroke and
TIA-patients.Methods/design
Trial objectives
In this trial, we test the hypothesis that the pragmatic
disease-management program STROKE-CARD designed
for ischaemic stroke and TIA patients is capable of (a)
preventing recurrent cardiovascular events by optimised
guideline-compliant secondary prevention and target level
achievement and (b) ameliorating health-related quality of
life (QoL) and patient-wellbeing by early detection and
consequent treatment of post-stroke complications.Study design and centres
STROKE-CARD is a randomised, controlled, open inter-
ventional phase III trial with blinded outcome assessment
[ClinicalTrials.gov NCT02156778] conducted in Austria.
It initially started as a single-centre study in January 2014
and was extended to a second centre in December 2014.
It compares two standards of post-stroke patient care,
both complying with the current state-of-the-art. The trial
does not involve experimental interventions but compares
usual with intensified care as specified below. Primary out-
come events are adjudicated based on pre-specified diag-
nostic criteria blinded to treatment allocation.
The two trial centres are located at the Departments
of Neurology at the Innsbruck University Hospital (IUH)
and the Hospital St. John of God in Vienna. IUH serves
as the comprehensive stroke unit for the entire federal
state of Tyrol (catchment area ≈ 1 Mio) and as a primary
stroke unit for the city of Innsbruck and 65 surrounding
suburban communities with approximately 0.3 Mio in-
habitants. Patients from this exclusive catchment area
represent an unselected cohort of ischaemic stroke and
TIA patients [5]. The Hospital St. John of God Vienna
houses one of the four comprehensive stroke units in
Vienna. The Viennese stroke network includes additional
six primary stroke units and serves the city of Vienna
with a catchment area of more than 1.8 Mio inhabitants.Study population
The study population comprises consecutive patients
with acute ischaemic stroke or TIA (ABCD2-Score ≥ 3)
[17] admitted to the two study centres. Patients are eli-
gible for inclusion irrespective of whether the index
event was a first or recurrent event. Ischaemic stroke is
ascertained using the American Heart Association cri-
teria based on clinical and imaging features [18].
All patients with ischaemic stroke or TIA admitted to
the study centres are screened for potential inclusion in
the STROKE-CARD trial during the first days of their
hospital stay and in most instances included before dis-
charge after signing an informed consent. Further details
on the inclusion and exclusion criteria are provided in
Table 1.
Table 1 STROKE-CARD inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients with acute ischaemic stroke or TIA (ABCD2 Score≥ 3 points)
Age≥ 18 years
Signed informed consent
Patients living outside the catchment area
Malignancy or other severe disease with life-expectancy less than the
expected duration of the trial
Drug addiction or severe alcohol abuse
Patients with permanent severe disability and low perspectives for
successful rehabilitation
(mRS [19] = 5 at discharge)
TIA transient ischaemic attack, mRS modified Rankin Scale [19]
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We block-randomise patients in a 2:1 ratio to receive the
STROKE-CARD program or standard care on the basis of
the exact date and time of the qualifying event, with the
durations of the blocks ranging from 4 to 8 weeks. The
target sample size is 2160 patients overall, 1440 patients in
the STROKE-CARD group, and 720 in the control group
(Fig. 1). We strive for inclusion of about 500 patients per
year. Patients are followed-up for 12 months, but we also
obtain consent from the patients to contact them later on
and extend follow-up for future research projects. Patients
who do not adhere to the extended standard care pro-
gram, especially do not attend the 3-month assessment,
are followed in the same way as adherent patients for pri-
mary and secondary outcome events.
Intervention
Standard care
In the control arm, patients are managed according to the
usual stroke care protocol [5] of the study centres which
includes: (a) detailed patient counselling and education
about stroke pathophysiology, risk factor management, life
style improvement and medication compliance by a stroke
specialist (involving the next of kin and caregivers if ap-
propriate); (b) provision of the complimentary book “After
a stroke” [20] dealing with all aspects of stroke care; (c) in-
dividual in-hospital advice by a dietitian for patients with
diabetes, severe dyslipidaemia, and obesity, and smoking
cessation support for heavy smokers; (d) provision of stan-
dardised information materials (e.g. for oral anticoagula-
tion therapy); and (e) provision at discharge of detailed
medical reports for the general practitioner as well as the
patient containing target levels for risk factor manage-
ment. Post-discharge risk-factor-management is per-
formed by the patient’s general practitioner. Only selected
high-risk patients are seen in the centres’ outpatient
clinics. A standardised 3-month telephone interview by a
study nurse for assessment of functional outcome (mRS,
Barthel Index, nursing allowance, life situation, support
services, medication) is part of the country-wide quality
program but has no interventional character [5]. As part
of the STROKE-CARD protocol, all patients undergo a
comprehensive standardised clinical visit 12 months after
recruitment.Stroke-CARD
In addition to the procedures listed above, the
intervention-arm includes two additional interventions:
(a) a three-month outpatient appointment with
standardised re-assessment of all risk factors and
re-evaluation of stroke aetiology, screening for post-
stroke complications (e.g. spasticity, foot-drop,
fatigue, pain, incontinence, communication problems,
depression and anxiety, impaired cognition, seizures,
fatigue, syncope, falls, fractures etc.), other health
problems and residual deficits, estimation of the
patient’s demand for nursing services and the
patient’s adherence to drug prescriptions. All this
information is used to optimise secondary prevention
[21–23] with best possible achievement of target
levels, to refine rehabilitation and treatment goals,
and to manage post-stroke complications. Further
details on the target levels are listed in Table 2.
Patient assessment and counselling is done by a
multidisciplinary team of physicians, nurses,
physiotherapists, occupational and speech therapists.
Treatment decisions are determined by experienced
stroke neurologists. The overall visit takes about
3–4 h. The general practitioner receives a detailed
medical report with precise instructions and
treatment goals. Additional 6-month and 9-month
visits are performed exceptionally (target < 5% of
cases) at the discretion of the study team in case of
medical need, complications requiring follow-up, or
very poor risk factor control.
(b) Patients are offered access to an interactive
password-protected web-based patient portal called
“My Strokecard” [https://ches.tirol-kliniken.at/cms/
]. If patients are unable to use a computer,
caregivers are asked to assist with the usage of “My
Strokecard”. The patient-portal has been designed
building on existing software for electronic patient-
reported outcome monitoring [24] and contains
three components: (i) An adapted version of the
‘post-stroke checklist’ for ascertainment of post-
stroke complications is available for screening
purposes at any time and pop up automatically
three weeks before the three- and twelve-month
Fig. 1 Patient flow and allocation
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questionnaires is already available before the
medical visit. (ii) A self-administered internet-based
tool for risk factor monitoring and patient self-
empowerment (i.e. blood pressure, body weight,
nicotine consumption, physical activity, LDL-C and
HbA1c in case of diabetes) automatically generates
feedback on target level achievement [tabular proto-
cols and simple graphs visualising the current stage
and time trends for the patient and GP, see
Additional file 1]. (iii) Extensive information and
educational materials on stroke pathophysiology,
symptoms and risk factor management are
provided.
During the in-hospital phase, clinical care does not dif-
fer between the two groups, with the exception of the
training for the use of “My Stroke Card” in the extended
care group before discharge.
There will be (i) a continuous monitoring of different
benchmarks, including the duration of hospital stay and
access to rehabilitation facilities to ensure that the two
groups do not receive differential attention and to min-
imise surveillance biases, and (ii) a monitoring of trial
progress by a data monitoring board.Outcome
Primary outcomes (Co-primary endpoint)
▪ Incidence of major cardiovascular events defined as
nonfatal stroke (ischaemic or haemorrhagic), nonfatal
myocardial infarction (including acute coronary
syndrome requiring emergency vascularisation), and
vascular death (i.e. sudden cardiac death and death
from acute myocardial infarction, ischaemic or
haemorrhagic stroke, heart failure, cardiovascular
procedures, pulmonary embolism, or peripheral artery
disease) within one year of the index event.
▪ Health-related QoL assessed by the European Quality
of Life-5 Dimensions (EQ-5D-3 L) overall health
utility score one year after the index event.Secondary outcomes
▪ Recurrent ischaemic or haemorrhagic stroke and TIA
(defined as transient neurological deficit < 24 h and
absence of DWI positive lesions on MRI) within one
year of the index-event.
▪ All-cause mortality at 12 months.
▪ Favorable functional outcome (mRS ≤2 and change in
mRS) at one year and at three months.
Table 2 Target levels and interventions for risk factors at the 3-month risk factor assessment
Condition Target Intervention to achieve the targets
Hypertension BP < 140/90 mmHg
BP < 130/85 mmHg in patients with diabetes,
renal impairment or small-vessel disease
Adjustment of anti-hypertensive medication
Information on supportive lifestyle changes
Written recommendations to and intensified
management by the GP
Dyslipidaemia LDL-C < 100 mg/dL
LDL-C < 70 mg/dL in very high-risk patients
Adjustment of statin dosage
Prescription of ezetimibe additionally to high-dose
statins (according to guidelines)
Involvement of a lipid-clinic and prescription of PCSK9
inhibitors (according to guidelines)
Individualised recommendations by a dietitian
Diabetes HbA1c < 7% Re-evaluation of the therapeutic regime by a diabetes-
specialist
Additional management by the GP, re-instruction in
correct administration of injectable pharmacological
agents
Individualised recommendations by a dietitian
Smoking Nicotine abstinence Motivational interviewing and counselling
Provision of informational material
Involvement of a psychiatric specialist for behavioural
or pharmacological therapy
Physical inactivity Physical activity of moderate to vigorous
intensity with an average of 40 min at least
3 times per week
Motivational interviewing
Provision of informational material
Non-adherence to drug prescriptions Adherence to drug prescription (proportion
of days covered ≥90%)
Motivational interviewing with information on indication
& therapeutic effect of current medication
Simplification of drug-regimes
Home support by nurses and/or relatives
Poor “stroke-knowledge” of patients
& family-members or caregivers
Information on stroke pathophysiology & individual
stroke mechanism
Provision of a book and standardised information material
Post-stroke complicationsa &
poor functional outcome
Improvement of QoL Individualised treatment & prevention of post-stroke
complications
Provision of further outpatient or inpatient rehabilitation
Re-assessment on nursing demands, social integration &
outpatient care
Involvement of a social worker
BP blood pressure, GP general practitioner, LDL-C low-density lipoprotein cholesterol, PCSK9 proprotein convertase subtilisin/kexin type 9, HbA1c glycated
haemoglobin, QoL quality of life
aspasticity, pain, risk of falling, post stroke-depression (PSD), fatigue, anxiety, dysphagia, social deprivation, post-stroke dementia
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i.e. mobility, self-care, usual activities, pain and
discomfort, anxiety and depression after one year.
▪ Achievement of predefined target levels in secondary
prevention 12 months after the index event: BP <
140/90 mmHg [< 130/85 mmHg in selected patients],
target HbA1c in patients with diabetes [mainly < 7.0%,
less stringent targets in elderly], nicotine abstinence,
LDL-C < 100 mg/dL [LDL-C < 70 mg/dL in high-risk
patients] [23], physical activity with an average of
40 min at least 3 times per week, platelet inhibitor or
anticoagulation according to ischaemic stroke
aetiology [in case of oral anticoagulation with vitamin
K antagonists: INR 2–3, time in therapeutic range
(TTR) > 70%], statins except for patients with
ischaemic strokes of non-atherosclerotic origin and
no evidence of atherosclerosis (e.g. vessel dissection),
medication adherence [proportion of days covered(PDC) ≥ 90%] [25]. The latter criterion focuses on
statins, platelet inhibitors other than aspirin (which is
typically purchased over the counter), antihypertensive
medication, oral anti-diabetic drugs, and
anticoagulation.
Clinical assessments and study protocols
The protocol uses validated and field-proven forms,
scales and questionnaires. All the study team members
are highly experienced and NIHSS- and mRS-certified.
The clinical baseline-assessment (entire study popula-
tion) and the outpatient appointment (3-month interven-
tion [intervention arm only] and 12-month outcome
assessment [entire study population]) will be performed
by trained health care professionals of the multidisciplin-
ary study team composed of experienced stroke neurolo-
gists, PhD-students, physiotherapists, and stroke nurses.
Data are collected prospectively according to pre-specified
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and storage and undergo subsequent quality checks and
validation (e.g. by hospital records and feedback from the
GP). All hospitals in the survey area dispose of electronic
records, to which study investigators were granted access
via protected data links according to the patients’ in-
formed consent.
The baseline assessment includes detailed documen-
tation of the following components: ischaemic stroke
aetiology [TOAST-criteria [26], Causative Classification
of Stroke [27]], stroke severity [NIHSS [28] on admission
and discharge], clinical syndrome [stroke/TIA symp-
toms, vessel territories], acute stroke therapy and recan-
alization procedures, pre-stroke disability and disability
on admission [mRS], prior cardiovascular events and co-
morbidities, cardiovascular risk factors (hypertension,
dyslipidaemia, smoking-status [current, former, never]
and burden [pack-years, Fagerstroem questionnaire
[29]], alcohol consumption [quantity, patterns, type of
beverages], diabetes [ADA criteria] [30], atrial fibrilla-
tion, physical activity [Baecke Physical Activity Ques-
tionnaire] [31]), family history of cardiovascular disease,
previous and current medication, cognitive function
[Mini-Mental State Examination [32] and Montreal Cog-
nitive Assessment [33]], depression [Beck Depression
Inventar, anxiety [Hospital Anxiety and Depression Scale
[34]], fatigue [Fatigue Severity Scale [35]], health related
quality of life [European Quality of Life-5 Dimensions
EQ5D-3 L [36]], anthropometric measures [body mass
index, waist–to hip ratio], repeated blood pressure re-
cordings [acute setting and before discharge],
ankle-brachial index, atherosclerosis of the carotid arter-
ies [intima-media thickness, plaque burden], [37] pulse
wave velocity [Complior® system], and routine laboratory
measures [including lipid profile, renal function, liver
function, thyroid function, cardiac markers, differential
blood count, coagulation diagnostics, and inflammation
markers].
The 3- and 12-month visits involve a neurological
evaluation with documentation of clinical deficits and
functional outcome [NIHSS, mRS, and Barthel Index
[38]], routine laboratory examination and assessment of
recurrent cardiovascular events, hospital stays and proce-
dures [interventional and surgical], falls and fractures, all
incident diseases and morbidities [including bleeding
events], current medication, adherence to prescribed
drugs, and risk factor control. Cognitive function, depres-
sion, anxiety, fatigue, and QoL all are re-evaluated [see
baseline assessment]. Carotid ultrasound [see baseline
protocol] is obligatorily repeated during the 12-month
visit and, if clinically indicated, also after three months.
Blood and urine samples are drawn after an overnight
fast and at least 12-h abstinence from smoking [during
the hospital stay and 3 and 12 months thereafter],immediately processed, used for routine testing, and
stored in a biobank [plasma, serum, whole blood, and
urine]. Samples are stored at − 80 °C in compliance with
the OECD guidelines and Austrian Bioethics Commis-
sion recommendations [39].
Sample size
Sample size calculations for this trial were based on the
primary composite cardiovascular disease endpoint. As-
suming a 1-year cumulative risk of 15% in the usual care
group, 2045 subjects are required to detect a 5% abso-
lute risk reduction (α = 0.05) with a 90% power.
Expecting an attrition rate of 15% (7.5% dropout rate
[withdrawal of consent] and a loss-to-follow-up of 7.5%),
we aimed to include a total of 2400 patients. Between
January 2014 and June 2017, 1866 patients were re-
cruited, with an attrition rate substantially lower than
expected (< 5.0% as opposed to the anticipated 15%). Ac-
cordingly, the data monitoring board recommended re-
vision of the recruitment goal from 2400 to 2160
patients. A sample size of 2160 patients provides the
trial with a 90% power to detect a difference of 0.03
points on the EQ-5D-3 L overall health utility score
(co-primary efficacy endpoint) assuming a standard devi-
ation of 0.2.
Statistical analyses
The primary efficacy analysis is based on time from hos-
pital discharge to first occurrence of primary composite
end-point as defined above. It is an unadjusted survival
analysis according to the intention-to-treat principle
with use of the log-rank test. Hazard ratios and 95%
confidence intervals will be estimated using Cox models
with the assumption of proportional hazards checked by
means of Schoenfeld residuals. Prespecified sensitivity
analyses include adjusted models and a per-protocol
analysis. Consistency of intervention effects in four pre-
specified subgroups (men and women, age groups, type
of index event, and patients with or without regular use
of My StrokeCard) will be assessed by means of test for
interaction. The continuous efficacy endpoint QoL will
be analysed with linear regression models.
Owing to the fact that our study attempts to encour-
age patients to adhere to current evidence-based preven-
tion guidelines and does not include experimental
treatment concepts, we do not perform a formal safety
analysis. We however analyze whether there are any dif-
ferences in the occurrence of potential side effects, risks
and consequences of intensified secondary prevention in
both study arms including (a) major bleeding [40], (b),
syncopes and fractures, (c) laboratory abnormalities
(ALT, CK, GFR), and (d) muscle-related outcomes. No
formal interim analysis will be performed. All re-
ported P values are two-sided.
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The risk of stroke recurrence within one year after ischae-
mic stroke or TIA is high and can effectively be reduced
by effective guideline-compliant secondary prevention.
Vice versa, poor adherence to guidelines leads to prevent-
able recurrent events, worse outcome and higher health
care costs. Post-stroke complications are frequent, often
remain unrecognised and contribute to stroke disability
and poor QoL.The STROKE-CARD concept
STROKE-CARD is the first comprehensive pragmatic
post-stroke disease management in Austria and, to our
knowledge, one of the largest interventions of its kind
worldwide. STROKE-CARD is addressing a real-life-cohort
of ischaemic stroke- and TIA-patients with the primary ob-
jectives of enhancing adherence to prevention guidelines
and thereby lowering rates of recurrent vascular events
and post-stroke complications, and improving functional
outcome and QoL. Whereas disease management pro-
grams traditionally rely on expert opinion, our initiative
strives for a rigorous scientific evaluation involving out-
come and health economy analyses. It pursues the concept
that optimal acute stroke care extends to a thorough
three-month assessment and individualised counselling.
We employ a multidisciplinary but lean and cheap inter-
vention leveraging contemporary e-technology and encour-
aging patient self-empowerment with the prospect of a
widespread implementation in case of success. Access to
Internet and social media is now broadly available and
STROKE-CARD offers web-based educational patient-
operated tools for risk factor to record and manage risk
factors combined with linkage of patient data to medical
caregivers. The STROKE-CARD concept was presented as
an abstract at the European Stroke Organisation Confer-
ence 2018 [41].Other post-stroke disease management programs
Previous trials on multimodal secondary prevention
strategies in ischaemic stroke or TIA-patients have
shown variable improvements in risk factor control or
medication adherence but most were not designed and
powered to analyse potential effects recurrent cardiovas-
cular disease and stroke events. An overview on trials fo-
cusing on multimodal secondary stroke prevention is
provided in Table 3. Limitations shared by these trials
include the usually limited sample size (443 median,
IQR 347.3) [42–50] and the common focus on TIA or
minor stroke patients only [48, 49, 51].
Only one large-scale study has been completed so far
[45] and enrolled more than 3800 ischaemic stroke and
TIA-patients in 47 hospitals in China. In spite of a better
adherence to statin-medications no difference in thehard clinical end points after one year of follow-up could
be demonstrated.
Two ongoing studies deserve special consideration: (i)
The Comprehensive Post-Acute Stroke Service (COM-
PASS) study, [52] a cluster-randomised trial involving 40
hospitals in North Carolina, plans enrolment of 6000 is-
chaemic and haemorrhagic stroke patients and investi-
gates potential effects of the COMPASS care model
(telephone follow-up, one clinic visit within two weeks
after discharge, and an individualised patient electronic
care plan) on the patient-reported 90-day functional out-
come (primary endpoint), hospital re-admission rates,
and 90-day mortality. (ii) The Intensified Secondary Pre-
vention intending a Reduction of Recurrent Events in
TIA and Minor Stroke patients (INSPiRE-TMS) study,
[51] from Germany intends to recruit 2082 patients with
minor stroke or TIA, provides up to eight appointments
in outpatient clinics and focuses on two-year recurrent
vascular events or vascular death.
Type and intensity of intervention vary widely among
the different trials. Several programs envisage nurse-led
home visits or telephone-based assessments for risk fac-
tor control [44, 47, 50]. The ICARUSS-strategy [43] in
Australia trusts on several pre-arranged GP visits
whereas the STANDFIRM-trial (n = 500), [46] a
community-based intervention, consists of educational
sessions, multiple follow-up assessments, and as tele-
phone interviews conducted by study nurses and general
practices. A recent intervention [49] has achieved a sub-
stantial and sustained (six months) reduction in global
vascular risk (Framingham Risk Score, Cardiovascular
Disease Life Expectancy Model) by non-physician pro-
vider case management. Digital health interventions (e.g.
telemedicine, web-based strategies, email and- mobile
phone-reminders) improved risk factor control in vascu-
lar diseases other than stroke [16].
Strengths and limitations
Key and in part unique features of STROKE-CARD are its
comprehensive focus on both recurrent vascular events (risk
factor control and compliance) and post-stroke complica-
tions and QoL, its lean and easily applicable intervention,
and the inclusion of moderate and severe ischaemic stroke
patients (all except those with permanent severe disability).
The primary analysis may be viewed as conservative in
two respects: [1] It relies on a short one-year follow-up
whereas potential effects are expected to increase over
time. Extension of follow-up is a decided goal and fund
raising is in progress [2]. Our program is realised within
the framework of a highly developed stroke care setting
and bears the challenge of a strong comparator group
with high-quality management of ischaemic stroke/TIA
patients. Although findings of our trial are not easily ex-
trapolated to less developed stroke systems, the potential
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the low-quality stroke care background.
Our program is focused on ischaemic stroke but may
serve as a model for other diseases sensitive to
post-discharge management.
In case of success, the next steps would be a refine-
ment of STROKE-CARD components and identification
of subgroups with a health benefit and cost effectiveness
in order to end up with a practicable tool for broad clin-
ical implementation in the whole of Tyrol, Austria and
beyond.
Additional file
Additional file 1: Pragmatic Trial of Multifaceted Intervention (STROKE-
CARD care) to Reduce Cardiovascular Risk and Improve Quality-of-Life
after Ischaemic Stroke and Transient Ischaemic Attack –Study protocol.
Excerpt of the interactive website “My Strokecard”. (DOCX 389 kb)
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